A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers

Trial Profile

A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Interleukin-15 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jun 2018 Planned End Date changed from 1 Apr 2020 to 1 Apr 2022.
    • 26 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Mar 2018 Planned number of patients changed from 44 to 52.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top